Autopsy report · NCT00758732

Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Poor accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 years 11 months after it had already started.
Ran for about 5 years 5 months before it stopped.
34 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Hellenic Oncology Research Group
Sponsor type: University, hospital or other
Conditions: Ovarian Cancer
Interventions: Docetaxel; Carboplatin; Docetaxel; Liposomal doxorubicin
Participants: 34
Sites: 12
Countries: Greece

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.